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High-grade gliomas (HGGs) are aggressive primary brain tumors with local invasive growth and poor clinical
prognosis in both adult and pediatric patients. Clinical response is compounded by resistance to standard frontline
antineoplastic agents, an absence of novel therapeutics, and poor in vitro models to evaluate these. We screened
a range of recently identified anticancer compounds in conventional adult, pediatric, and new biopsy-derived HGG
models. These in vitro lines showed a range of sensitivity to standard chemotherapeutics, with varying expression
levels of the prognostic markers hypoxia-induced factor (HIF) 1α and p53. Our evaluation of lead DIVERSet library
compounds identified that JAG-6A, a compound that was significantly more potent than temozolomide or
etoposide, was effective against HGG models in two-dimensional and three-dimensional systems; mediated this
response by the potent inhibition of topoisomerase Iiα; remained effective under normoxic and hypoxic
conditions; and displayed limited toxicity to non-neoplastic astrocytes. These data suggest that JAG-6A could be
an alternative topoisomerase IIα inhibitor and used for the treatment of HGG.
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1936-5233/19Introduction
In 2015 alone, 22,850 adults (12,630 men and 10,280 women) were
diagnosed with brain and other central nervous system (CNS) cancers
in the United States, with 15,320 resulting in patient death [1].
High-grade gliomas (HGGs) account for 52% of all primary brain
tumors and in children occur at a frequency of 5.7 cases per 100,000
[2]. Adult HGG (aHGG) treatment comprises a multidisciplinary
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chemotherapy [3]. Despite this, mean patient survival is less than
15 months [4,5]. The current standard chemotherapeutic for aHGG
treatment is the DNA alkylating drug temozolomide (Temodal)
(TMZ) [6,7]. The addition of TMZ to the surgical and radiotherapy
regimen (the “Stupp protocol”) demonstrated a significant patient
survival benefit with a median increase in survival of 2.5 months [8].
However, this protocol yields a 24-month progression-free survival of
just 14%, where a discernible TMZ response was only noted in
tumors exhibiting O6-methylguanine DNA methyltransferase
(MGMT) promoter methylation [9]. Irrespective ofMGMT promoter
methylation, almost all patients demonstrate disease relapse and eventual
progressive disease. Pediatric HGG (pHGG) is significantly different
from adult disease, where recent substantive genomic and epigenomic
studies has resulted in an almost complete reclassification of childhood
brain tumors, incorporating diverse histological andmolecular-phenotype
differences [10–12]. Both adult and pediatricHGGs present with areas of
attenuated vascularization forming hypoxic regions (areas of insufficient
oxygenation) [13–15]. This environment drives the modulation and
stabilization of hypoxia induced factor (HIF)-1α, a transcription factor
implicated in oncogenesis, angiogenesis, proliferation, and invasion.
HIF-1α expression correlates with poor clinical prognosis, in part due to
co-inhibition of the p53 mediated proapoptotic network in HGG
[16,17]. While TP53 mutations have not been associated with aHGG
patient prognosis, approximately 40% of pHGGs are associated with
TP53 mutations [18] [12], and this correlated with patient prognosis
[19–21].
Similar to aHGG patients, pHGG treatment consists of an
aggressive multidisciplinary approach that incorporates surgery (if
possible), radiotherapy, and chemotherapy [22]. Prognosis remains
dismal with 5-year progression-free survival between 10% and 30%
[23–26]. In contrast to aHGG where TMZ treatment has a clear
therapeutic benefit, within the pHGG patient population, TMZ
regimens revealed no impact on patient outcome [27,28]. Conse-
quently, pHGG chemotherapy regimens incorporate procarbazine,
lomustine, etoposide, cisplatin, and vincristine [3,27,29–31]. The
incorporation of etoposide (in combination with cisplatin) represents
a common treatment modality for patients and is a compelling
therapeutic agent. Etoposide, a topoisomerase II poison, induces
double-strand DNA breaks by increasing the amount of cleavable
topoisomerase II:DNA complexes. The level of these complexes is
topoisomerase II concentration dependent, where it is far higher in
rapidly dividing cancer cells versus non-neoplastic cells [32].
Topoisomerase II inhibitors have been extensively tested against a
number of cancer types and have shown promise against aHGG
[33,34]. One of the critical limitations for topoisomerase II poisons
relates to their pharmacokinetic profile and poor blood–brain barrier
permissiveness. Despite these limitations, there have been a number
of approaches to enhance the delivery of these agents into the CNS.
This includes convection enhanced delivery [35]. Importantly, the
identification of novel therapeutics, particularly topoisomerase II
poisons with a significantly lower molecular weight (with increase
solubility), would be of significant interest to the field.
In silico analysis using the DIVERSet compound library from
Chembridge (San Diego, CA) identified a number of lead anticancer
agents for further analysis [36]. Here we performed in vitro
two-dimensional (2D) and three-dimensional (3D) analysis of
conventional and recently obtained, biopsy-derived aHGG cells as
well as established pHGG cells following exposure to each lead agent.We evaluated cell viability posttreatment with each compound and
evaluated the effect of these compared to TMZ, etoposide,
vincristine, and gemcitabine. We revealed that the lead agents were
potent inhibitors of topoisomerase II and, consistent with this cellular
target, examined the HIF-1α and p53 signaling networks in key
HGG lines following exposure to these compounds.
Methods and Methods
Tumor Specimens and Primary Tumor Cultures
Following informed consent and in accordance with the LREC
review board (11/SC/0048), HGG samples were obtained from
patients undergoing biopsy surgery at Kings College Hospital NHS
Foundation Trust (London, UK).Tumors were classified based on
WHO criteria after examination by neuropathologists. The tumor
mass was mechanically dissociated into explant clumps, allowing
neoplastic cells to colonize the flask. Biopsies were cultured in
DMEM with 10% heat-inactivated FCS. Upon establishment of cell
cultures, a combined STR profile was conducted for each adult HGG
(Agilent Bioscience). All experimental protocols were approved by the
University of Portsmouth, Faculty of Research.
Chemotherapeutics and Cell Culture
TMZ (T2577) and vincristine (V0400000) were from Sigma-Aldrich.
Gemcitabine (S1714) was from SelleckChem. JAG-6A, CC-I, JAG-32,
and JAG-79were providedbyOpalOncology (Cambridge,UK).U87MG
was obtained from theATCC.KNS42 andSF188 cells were obtained from
Professor Chris Jones (Institute of Cancer Research, London, UK).
UP-029, SEBTA-003, SEBTA-023, and SEBTA-025 were cultured in
DMEM (61965 Fisher Scientific) supplemented with 10% HIFBS
(F7524-500ML Sigma-Alrich). SC1800 and CC2565 non-neoplastic
astrocytes were purchased from Lonza and maintained in astrocyte growth
medium supplemented with SingleQuots (CC-3187 Lonza) including
(CC-4123) rhEGF, insulin, ascorbic acid, and L-glutamine. Cells were
cultured under normoxic (21%) or hypoxic (1%) O2.
Spheroid Formation and Staining Assay
We modified the Sirenko and Montenegro et al. protocol [37,38].
Cells were seeded in ultra-low adherence plates and treated with
compounds after 12 hours. Spheroids were stained in 4 μM Calcein
AM (Fisher Scientific, C1430), 50 μg/ml propidium iodide (PI)
(Fisher Scientific, P3566), and 33 μM Hoechst 33342 (Fisher
Scientific, H1399) in phenol-free, serum-free DMEM. Imaging was
conducted on InCell 6000 at 10× magnification, 4 fields with 15%
overlap, 13 z-stacks, and 20 μM per step. Z-stacks were compressed
with maximum projection, extended focus algorithm, to a single
in-focus image. Four fields were stitched to a single image. Each
individual stained image is included in Supplemental Figure 1.
MTS Cell Viability Assay
Cells were seeded in triplicate in a 96-well plate. Twenty-four
hours postseeding, cell lines were treated at varying dosages of each
therapeutic agent. MTS assay (G3580 Promega) was conducted at
indicated time points following the manufactures guide. Absorbance
at 490 nm was recorded on BMG Labtech Polarstar.
Annexin V/propidium Iodide Apoptosis Assay
Cells after the treatment with each agent were collected, and the
cell concentration was determined using a Countess II FL (Thermo
Fisher, UK). Cells were centrifuged at 400g for 5 minutes, and the
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400g for 5 minutes, and the pellet was resuspended in 100 μl
Annexin V binding buffer. Annexin V-CF488A conjugate was added
to the cells including Hoechst (final concentration: 10 μg/ml) and
mixed by pipetting. Cells were incubated at 37°C for 15 minutes.
Following incubation, cells were centrifuged at 400g for 5 minutes.
The cell pellet was resuspended in Annexin V binding buffer and
centrifuged again, and the pellet was resuspended in Annexin V
supplemented with 10 μg/ml PI. Samples were run and analyzed
using a NucleoCounter NC-3000 (Chemometec, Denmark).
Western Blot Analysis
Total protein was harvested using RIPA buffer (89900,
Thermo-Fisher) and 1× protease inhibitor cocktail (78442
Thermo-Fisher). Primary antibodies HIF-1α (ABE279 Millipore),
p53 (DO1, sc-126 SCBT), or β-actin (sc-47778 SCBT) were added
to the membrane overnight. Secondary antibody was added (LICOR)
at 1:10,000 dilution for 1 hour. Membranes were imaged on Odyssey
CLX (Licor). All full-length gels and blots are included in our
Supplemental Information file (Supplemental Figures 2-4).
Quantitative Real-Time PCR
Total RNA was extracted (RNAeasy, 74104 Qiagen) and
quantified using RNA6000 chip arrays (Agilent Bioscience).
Real-time PCR was performed per sample in triplicate on a Roche
LightCycler 96. Primers are as follows: PUMA (fwd 5-gacctcaacgca-
cagtacga-3 and rev 5-tgggtaagggcaggagtc-3), Bax (fwd 5-ctgacgg-
caacttcaactg-3, rev 5-cactgtgacctgctccagaa-3). p21 (fwd
5-ggaagaccatgtggacctgt-3, rev 5-aagatgtagagcgggccttt-3). Aldolase c,
(fwd 5-tctctcaacctcaat-3, rev 5-agtacatagc-3) . HEK2 (fwd
5-tcgcatctgcttgcctacttc-3, rev 5-cttctggagcccattgtccgt-3), and
GAPDH (fwd 5-gagtcaacggatttggtcgt-3, rev 5-ttgattttggagggatctcg-3).
Data analysis was carried out using the 2−ΔΔCT method [39].
Topoisomerase IIα Decatenation Assay
Kinetoplast DNA (kDNA) decatenation assay was performed using a
Topopoisomerase II assay kit (TopoGEN, Inc., Port Orange, FL)
according to the manufacturer's instructions. Topoisomerase IIα
decatenates kDNA which consists of highly catenated networks of circular
DNA in an ATP-dependent reaction to yield individual minicircles of
DNA. In brief, for topoisomerase IIa–mediated kDNA decatenation assay,
the 20-μl reaction mixture contains the following components: 50 mM
Tris–HCl, pH 8.0, 150 mM NaCl, 10 mM MgCl2, 0.5 mM dithio-
threitol, 30 mg/ml bovine serum albumin, 2 mMATP, 260 ng of kDNA,
several concentrations of compounds, and 4 U of human topoisomerase
IIα. The final concentration of 0.5% (v/v) DMSO was used.
Molecular Modeling Study
The molecular modeling studies were based on the X-ray crystal
structure of human topoisomerase IIα (5BTD). Calculations were
performed using the program Molecular Operating Environment
(Chemical Computing Group Inc., Montreal, Canada). Ligand
binding energies in kcal/mol were calculated using force field
refinement (Amber12EHT) following initial placement via the
“Triangle Matcher” placement methodology.
Scanning Electron Microscopy
Spheroids were fixed with 2.5% glutaraldehyde and 2%
paraformaldehyde in phosphate buffer (0.1 M, pH 7.4) and treatedwith 1.5% potassium ferrocyanide and 1% osmium tetroxide, then
with 1% osmium tetroxide and a final 1% aqueous uranyl acetate.
Spheroids were imaged at 80 kV on Zeiss EVO MA10 SEM.
Data Analysis and Statistics
In vitro experiments were analyzed (GraphPad Prism) and are
represented as mean values ± SD, indicating the number of
experiments carried out for each assay. Statistical significance has
been calculated using Student's t test, (*P ≤ .05), two-tailed ANOVA
analysis, or the log-rank test for Kaplan-Meier survival analyses.
Results
Conventional Chemotherapeutics Significantly Reduce aHGG
Cell Viability
We obtained aHGG-derived biopsy material and isolated in vitro
cell lines designated UP-029, SEBTA-023, SEBTA-025, and
SEBTA-003. Each was DNA fingerprinted using a combined short
tandem repeat and fragment-length amplification [40]. We included
the human glioma cell line U87MG in our studies. While the
U87MG model has been questioned, U87MG is HGG in origin and
is a widely used in vitro model for preclinical testing [41,42].
U87MG cells were exposed to TMZ, gemcitabine, etoposide, or
vincristine for 96 hours under normoxic conditions (Figure 1A).
U87MG cells were refractory to TMZ (EC50 = 15.8 μM),
gemcitabine (EC50 = 103.6 μM), and etoposide (76.4 μM), although
they were sensitive to vincristine (EC50 = 0.315 nM). We questioned
if any of our biopsy-derived aHGG cell lines were sensitive to these
standard frontline chemotherapeutics (Figure 1, B-E). The most
potent chemotherapeutic tested was vincristine. The UP-029 aHGG
cells displayed sensitivity to TMZ (Figure 1B), whereas both
SEBTA-025 (Figure 1C) and SEBTA-003 (Figure 1D) aHGG cell
lines were refractory to this chemotherapeutic. In contrast, the
SEBTA-023 aHGG cells were highly resistant to all chemotherapeu-
tics except vincristine (Figure 1E).
Novel Anticancer Agents Mediate a Potent Cytotoxic Response
in Adult HGG
We next questioned if any of our lead DIVERSet anticancer agents
[termed JAG-6A, CC-I (JAG-31), JAG-32, and JAG-79] (Figure 2A)
would demonstrate an anti-HGG effect in the U87MG model
(Figure 2B) or in our novel biopsy lines (Figure 2, C-F). The U87MG
cells showed sensitivity to the JAG agents, in particular JAG-6A
(EC50 3.6 μM) and CC-I (EC50 7.4 μM). Similarly, JAG-6A was the
most potent therapeutic in our novel in vitro models. We next
compared the average EC50 value at 96 hours posttreatment
following the single exposure of each cell line to TMZ, etoposide,
or JAG-agent (Figure 2G). For each in vitro cell line, JAG-6A was
significantly more effective than TMZ or etoposide. The
biopsy-derived HGG cell lines were significantly more resistant to
these fronttline chemotherapeutics when compared to the widely
utilized U87MG cell line. The SEBTA-023 aHGG model was highly
resistant to all compounds tested.
Following exposure to each agent, we examined cell morphology
(Figure 2H). Twenty-four hours following JAG-6A treatment, each
biopsy-derived aHGG cell line displayed morphology changes, including
rounding up,membrane blebbing, andmonolayer detachment (Figure 2H
panel 3). This phenotype was not as pronounced 24 hours posttreatment
with CC-I or JAG-79 (Figure 2H panel 4 and 6). No cell morphology
changes were noted following JAG-32 exposure (Figure 2H panel 5).
Figure 1. Novel biopsy-derived aHGG cell lines display varying sensitivity to the chemotherapeutics temozolomide, gemcitabine, and
vincristine. (A) U87MG, (B) UP-029, (C) SEBTA-025, (D) SEBTA-003, and (E) SEBTA-023 were seeded in 96-well plates overnight. The next
day, cells were treated with temozolomide (≤128 mM), gemcitabine (≤330 mM), or vincristine (≤1 mM) in DMEM. Ninety-six hours
posttreatment, loss of cell viability was assessed by CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). Data
presented as mean average of n = 3 ± SD.
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detachment, and cell death were noted post-TMZ exposure. We
questioned the mechanism of cell death following exposure to each JAG
agent. Our aHGG lines were treated with TMZ or each JAG agent up to
96 hours. Annexin V/PI staining was conducted, and in agreement with
our previous data, we noted a significant increase in Annexin V and
AnnexinV/PI staining posttreatment with each compound (Figure 2I). For
each in vitromodel, AnnexinV and dual AnnexinV/PI stainingwas highestfollowing JAG-6A treatment. TMZ, CC-I, and JAG-32 exposure each
induced limited Annexin V and Annexin V/PI staining.
JAG Anticancer Agents Are Effective Against Pediatric HGG
In Vitro Models
Having observed that some JAG agents were effective in various
aHGG models, we questioned if these agents were effective against
pHGG. KNS42 or SF188 (both grade IV) cells were treated with JAG
agents (Figure 3, A-B). Similar to our aHGG cells, KNS42 cells
Figure 2. Novel JAG anticancer agents demonstrate a differential and significant anti-aHGG response. (A) Chemical structure of each JAG
agent used in this study. (B) U87MG cells (5×103 per well) were seeded overnight and treated the following day with JAG-6A (black), CC-I
(blue), JAG-32 (green), or JAG-79 (purple) at≤1000 μM. Ninety-six hours posttreatment, loss of cell viability was assessed by CellTiter 96
AQueous One Solution Cell Proliferation Assay (Promega). Data presented as average of n = 3 independent studies ± SD. (C-F) JAG
agent susceptibility was determined for each novel aHGG model. (G) Average EC50 values (±SD) for TMZ and each JAG agent were
determined. Two-tailed ANOVAs was conducted, and P values are shown for each comparison; n = 3. (H) Representative microscopy
(×10) images of UP-029 cells. UP-029 aHGG cells were seeded (1×104). The next day, cells were treated with indicated agents (10 mM
TMZ or 30 μM per JAG agent) and imaged (up to 24 hours) at 37°C under normoxic conditions. Images were recorded using EVOS FL
Auto (Life Technologies). (I) Apoptosis assays were conducted for each indicated cell line 24 hours post 30 μM treatment with each JAG
agent. Annexin V/PI staining was conducted and apoptosis status was determined using an NC-3000 counter; n = 3 ± SD.
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being the most potent compound tested. SF188 cells showed notable
resistance to these therapeutics, exhibiting sensitivity at only the very
highest tested drug concentrations. We observed that pHGG cell
morphology changed following JAG agent exposure consistent with
cell viability (Figure 3, C and D). JAG-6A induced the most
prominent change in KNS42 cell morphology 24 hours posttreat-
ment, characterized by extensive rounding up and monolayer
detachment. We conducted Annexin V/PI staining in our pHGG
cells following treatment with each JAG-agent (Figure 3D). We noted
that, 24 hours posttreatment, there was a significant increase in bothearly and late apoptotic cell populations. As we would predict from
our previous data, limited apoptosis was detected in JAG agent–
treated SF188 cells.
JAG Anticancer Agents Are Well Tolerated by Non-Neoplastic
Astrocytes
A critical consideration for any therapeutic is toxicity to non-neoplastic
cells. We questioned the sensitivity of the non-neoplastic astrocyte cell
line CC2565 to each conventional therapeutic (Figure 3E) and JAG agent
(Figure 3F). TMZand JAG agents were well tolerated; however, CC2565
cells displayed significant sensitivity to vincristine.
Figure 3. JAG agents mediate a potent anti-pHGG response with limited toxicity to non-neoplastic astrocytes. (A) KNS42 and (B) SF188
pHGG cells treated with each JAG agent. After 96 hours, loss of cell viability was determined by CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega). Representative microscopy (×10) images of (C) KNS42 and SF188 cells. Cells were treated with indicated
agents (30 μM per JAG agent) and imaged (up to 24 hours) at 37°C under normoxic conditions. Images and films were recorded using
EVOS FL Auto (Life Technologies). (D) Apoptosis assays were conducted for each indicated cell line 24 hours post 30 μM treatment with
each JAG agent. Annexin V/PI staining was conducted, and apoptosis status was determined using an NC-3000 counter; n = 3 ± SD. (E
and F) Dose-response curves for non-neoplastic CC2565 cells following exposure to TMZ (≤128 mM), vincristine (≤1 mM), or individual
JAG agents ≤1000 μM in complete astrocyte growth medium. Data presented as average of n = 3. Error bars indicate ±SD.
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In addition to non-neoplastic cell tolerance, any HGG therapeutic
must remain effective under hypoxic (1%) O2 conditions. To address
this question, we examined cell viability posttreatment under both
normoxic (21%) and hypoxic (1%) O2 conditions. Taking this into
consideration, we determined that there was no significant difference
in EC50 value for each JAG agent under hypoxic conditions. Both
JAG-6A and CC-I remained effective under this condition (Figure 4,
A-B). Supporting our previous data, SF188 cells showed little to no
response to each JAG agent irrespective of oxygenation levels (Figure
4C). For each of our tested cell lines, there was no statistical difference
between EC50 values for any of the tested agents under either hypoxic
or normoxic conditions.Differential Prognostic Protein Expression Occurs in Adult and
Pediatric HGG Models
Based on these hypoxia studies, we next assessed HIF-1α protein
expression under both normoxic and hypoxic conditions (Figure 4D).
Under normoxic conditions, UP-029, SEBTA-023, and SEBTA-003
aHGG cells demonstrated high HIF-1α protein expression. KNS42
and SF188 pHGG cells also had detectable HIF-1α protein
expression under normoxic conditions, a characteristic indicative of
poor clinical prognosis (Figure 4E). Non-neoplastic CC2565 cells
showed little HIF-1α protein expression under normoxic conditions,
although after hypoxic incubation, they showed protein accumulation
(Figure 4F). We questioned if this accumulation correlated with
HIF-1α–dependent gene transcription. Consistent with our HIF-1α
data, there was expression of aldolase c and HEK2 under normoxic
and hypoxic conditions in HGG (Figure 4G). In contrast to aHGG
cells, a significant increase in aldolase c and HEK2 transcription in
non-neoplastic astrocytes was observed after hypoxic incubation.Under normoxic conditions, there was significant variation in the
total p53 protein level in our cell lines (Figure 4, D and E). There was
detectable total p53 in the UP-029 cells, while the SEBTA-023 cell
line had little to no detectable total p53. SF188 cells showed an
appreciably lower, albeit specific, band. We questioned if our HGGs
demonstrate p53 accumulation and/or activation posttreatment with
each JAG agent or TMZ (Figure 4H). We observed the accumulation
of total p53 after JAG-6A, CC-I, or JAG-32 exposure in the UP-029
aHGG cells. Both SEBTA-023 and SF188 showed no detectable total
p53 and suggest, with our previous data, that there was a p53
dependency for these anticancer agents. We questioned if there were
any changes in p53-dependent gene expression, in particular, those
that direct apoptosis or cell cycle arrest (Figure 4I).
We found that there was little to no induction of p21 transcription
but significant expression of PUMA and Bax consistent with the
apoptosis and cell death previously described. Similarly, we detected
PUMA and Bax transcription following TMZ or etoposide exposure
(Figure 4J).JAG-6A Mediates a Potent Cytotoxic Response in Adult and
Pediatric HGG 3-D Spheroids
Having revealed a strong anti-aHGG response post-JAG-6A
treatment, we questioned if the effectiveness of this compound
when used to treat 2D cell cultures was conserved in 3D models. We
established two 3D HGG spheroid models: one adult, (UP-029) and
one pediatric (KNS42). Both formed robust spheroids, observed by
confocal (Figure 5A) and scanning electron microscopy (Figure 5B).
Spheroids were established and, 12 hours postdevelopment, exposed
to JAG agents or TMZ (Figure 5C). The percentage of live cells in
mock treated KNS42 and UP-029 spheroids remained high (87% ±
5.26% and 96.0% ±1.957%) up to 72 hours (Figure 5D). A
significant increase in the percentage of dead cells post JAG-6A
Figure 4. JAG agents are effective under hypoxic conditions, while novel aHGG models express differential levels of HIF1α and p53. Average
EC50 values (±SD) at 96 hours posttreatment for TMZ and each JAG agent were determined under normoxic (21% O2) or hypoxic (1% O2)
conditions. (A) UP-029 aHGG, (B) KNS42, and (C) SF188 pHGG cells; n = 3. Two-tailed ANOVA was conducted for each pair; all comparisons
were not significant. (D) Novel aHGG cells, (E) pHGG cells, and (F) non-neoplastic astrocytes were cultured under normoxic (NT) or hypoxic (1%
O2) conditions for up to 72 hours, and total protein lysates were analyzed byWestern blotting. (G) Indicated cell lines were cultured under either
normoxic (21% O2) or hypoxic (1% O2) conditions for 24 hours. Cells were collected at the end of the incubation. RNA was extracted and
qRT-PCR for aldolase c andHEK2mRNAwas analyzed; n = 3. Shown are fold change in aldolase c orHEK2 relative toGAPDH. (H) (left) UP-029
aHGGcellswere cultured under normoxic conditions and exposed to 10 μMJAG-6A, CC-I, JAG-32, or TMZ up to 24 hours. (Middle) UP-029 cells
were treated with 10 μM JAG-6A or TMZ up to 24 hours. (Right) KNS42 cells were treated with 10 μM JAG-6A or TMZ up to 24 hours. Total
protein lysates were analyzed byWestern blotting for total p53 or β actin. (I) UP-029 aHGG cells were cultured under normoxic conditions (21%
O2) and exposed to 10 μMof each JAG agent up to 12 hours. Expression of p21, PUMA, andBaxmRNAwasmeasured; n = 3. Shown are fold
change in eachgene relative toGAPDHmRNAof chemotherapy-treated versusmock-treated cells normalized to 1.0. (J) UP-029 aHGGcellswere
cultured under normoxic conditions (21%O2) and exposed to 10mMof TMZ or 30 μMgemcitabine up to 12 hours. Cells were collected at the
end of each incubation. RNA was extracted and qRT-PCR for PUMA and BaxmRNA was analyzed. n = 3, error bars indicate ±SD.
Translational Oncology Vol. 12, No. 10, 2019 DIVERSet JAG Compounds in High-Grade Glioma Howarth et al. 1381
1382 DIVERSet JAG Compounds in High-Grade Glioma Howarth et al. Translational Oncology Vol. 12, No. 10, 2019treatment (UP-029, 44.321% ± 6.254% and KNS42, 88.1% ±
4.379%, respectively) was noted. The remaining JAG agents showed
only a modest increase in cell death up to 72 hours. As we observed in
our 2D studies, JAG-6A–treated spheres displayed a significantly
increased total sum of dead cells (Figure 5E). Based on these data, we
concluded that JAG-6A retained efficacy in 3D HGG models. In
contrast to our 2D studies where CC-I instigated a significantreduction in the viability of UP-029 cells, in UP-092 3D spheroids,
CC-I effectiveness was significantly attenuated. These data raised the
hypothesis that the reduced surface area of the spheroid or the
diffusion of CC-I through the cell mass was diminished. UP-029
aHGG showed a significant increase of PUMA and Bax transcription
post JAG-6A treatment of the spheroids and a significant increase in
Bax transcription post TMZ exposure (Figure 5F). Consistent with
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of either PUMA or Bax in our 3D spheroids.
Our data revealed that JAG-6A directed a clear anti-HGG response
in both 2D and 3D models independent of the environmental
oxygenation conditions. However, it remained elusive as to how
JAG-6A could elicit this response. To answer this question, we
conducted molecular modeling studies. We noted that, with the
exception of JAG-79, each JAG agent bound to human topoisom-
erase IIα. The predicted binding location for JAG6A, CCI, and
JAG32 was inside the topoisomerase IIα cavity, where we
hypothesized that they may function as an inhibitor (Figure 5G).
Etoposide (a known topoisomerase Iiα) poison and chemotherapeutic
agent also bound in this cavity. Whereas the best binding energies
(kcal/mol−1) for JAG6A, CCI, and JAG32 were found to be inside
the same region of space within topoisomerase IIα (Figure 5H), the
JAG79 molecule was outside of this region. The modeling profile and
location for JAG-79 in part suggest a compelling reason why the
effectiveness of this compound was significantly worse than all of the
other JAG agents examined. We performed kDNA decatenation
assays to determine the ability of these compounds to inhibit
topoisomerase IIα enzyme activity. As we predicted, etoposide
potently inhibited topoisomerase IIα. Strikingly, we observed that
JAG6A, CC-I, and JAG32 inhibited topoisomerase IIα activity in a
dose-dependent manner. At concentrations ≈50 μM, CC-I–inhibited
topoisomerase IIα catalyzed kDNA decatenation, but noticeably,
both JAG6A and JAG32 inhibited topoisomerase IIα kDNA
decatenation at 5 μM (Figure 5I). We note that JAG79 had no
effect on topoisomerase IIα kDNA decatenation, consistent with the
predicted inability to bind within the topoisomerase IIα cavity. These
data indicated that the anti-HGG effect mediated by these agents, in
particular JAG6A, is by the potent inhibition of topoisomerase IIα.
Discussion
In both adult and pediatric patients, HGG treatment efficacy is
extremely limited due to widespread resistance to conventional
chemotherapeutics. Novel agents that are more potent than those
currently available (including TMZ and etoposide) are urgently
needed, in particular, agents that are less toxic to non-neoplastic cells.
Here we have compared a number of novel anticancer agents to
various conventional frontline chemotherapeutics. We conducted this
evaluation using a range of classic and new patient-derived aHGG cell
lines. Furthermore, we included two pediatric HGG in vitro models.
We examined the anticancer effectiveness of each compound
including the level (and activation) of HIF-1α and p53. UsingFigure 5. Novel aHGG models form spheroids. Adult/pediatric HGG s
of 5×103 UP-029 aHGG or KNS42 pHGG cells were cultured under u
lines formed dense, highly viable spheroids. (B) SEM of each spheroid
or KNS42 spheroids were treated with TMZ (10 mM) or JAG agents (3
live, and dead cells was conducted (see Methods). (D) Percentage of
number) of dead cells (per spheroid/micron2) is presented as mean ±
adherence conditions at 21% O2 and then exposed to 10 mM of T
collected at the end of each incubation. RNA was extracted, and p21,
ANOVA was conducted, and P values are shown for each compariso
binding cavity of topoisomerase IIα is shown in yellow. Topoisome
binding site. (H) Binding energy (kcal/mol−1) for each JAG agent and e
of the topoisomerase IIα cavity. (I) The JAG agent concentration-de
decatenation. All experiments were carried out according to instructio
of enzyme, 0.26 mg of DNA substrate, and the indicated concentratio
Different topological forms exhibited different mobility as indicated.molecular modeling and enzymatic assays, we identified that
topoisomerase IIα was the cellular target of our novel agents and
that the lead JAG compound (JAG-6A) was a potent inhibitor of this
enzyme. Consistent with this inhibition, JAG-6A directed the
strongest anti-HGG response, and this response was not diminished
when cells were cultured and then treated under hypoxic (1% O2)
conditions. Consistent with this efficacy under hypoxic conditions,
when adult or pediatric HGG lines were cultured in 3D spheroids,
JAG-6A mediated a potent anti-HGG response. Interestingly,
JAG-6A had a significantly lower EC50 compared to TMZ when
UP-029 or KNS42 3D spheroids were treated. JAG-6A exposure
triggered a significant induction of the p53-dependent target genes
PUMA and Bax with a concomitant increase in both proteins up to
24 hours. We did not observe an increase of p21 transcription,
consistent with the induction of apoptosis we report and the known
prosurvival role of p21 [43] [44,45].
Within our small adult cohort, all patients underwent the Stupp
protocol post biopsy surgery. Patients with biopsy lines that
responded poorly (or not at all) to JAG-6A (as well as TMZ) had a
significantly worse clinical outcome. UP-029 and SEBTA-025
showed a potent response to JAG-6A (and TMZ). SEBTA-003
(with unmethylated MGMT) was resistant to TMZ, although it was
sensitive to JAG-6A, highlighting a divergent mechanism of action (a
topoisomerase Iiα inhibitor compared to a DNA alkylating agent).
SEBTA-023 was highly resistant to conventional treatments and
JAG-6A, likely in part to the p53 status of this model, a finding
consistent with reports demonstrating that topoisomerase IIα
inhibitors direct p53-dependent cell death [46–48]. There are a
number of processes that might modulate cancer susceptibility to
etoposide, including the level of topoisomerase II expression (at the
level of both transcription and translation), the DNA binding of
topoisomerase II, its activity following DNA binding, and topoisom-
erase II posttranslational modifications. Mutations in the Kelch-like
ECH-associated protein 1 (KEAP1), the SWI/SNF complex (a
nucleosome remodeling complex), and the methyltransferase EZH2
influence topoisomerase II at a transcriptional level, modifying
susceptibility to topoisomerase poisons [49–52]. An extensive
evaluation of cell line sensitivity to etoposide highlighted that for
many classical high-grade glioma lines, their response were
comparable to that of small cell lung cancer and myeloma, both
cancers that have traditionally been treated with etoposide [35]. At
present, there are a number of investigations of topoisomerase poisons
in combination with novel delivery mechanisms. This includes
pediatric brain tumors, where laser interstitial thermal therapy ispheroids are sensitive to specific JAG anticancer agents. (A) A total
ltra-low adherent conditions. Twenty-four hours later, both in vitro
model; left panel scale bar: 50 μm, right panel scale bar. (C) UP-029
0 μM). Seventy-two hours posttreatment, triple staining for nuclear,
PI-positive (dead) cells are presented as mean ± SD. (E) Sum (total
SD. n = 6. (F) UP-029 adult GBM cells were cultured in ultra-low
MZ or 30 μM of each JAG agent up to 12 hours. Spheroids were
PUMA, and Bax expression was analyzed. n = 3. For all, two-tailed
n. (G) Structure of each agent docked into topoisomerase IIα. The
rase is shown as the brown-colored ribbon with residues on the
toposide. Note, themost energy-stable binding for JAG79 is outside
pendent inhibition of human topoisomerase IIα–mediated kDNA
ns from the Topogen kit (Port Orange, FL). Reactions contained 4 U
n of each agent dissolved in DMSO (0.5% final concentration (v/v)).
Etoposide was included as a positive control.
1384 DIVERSet JAG Compounds in High-Grade Glioma Howarth et al. Translational Oncology Vol. 12, No. 10, 2019applied to disrupt the blood–brain barrier and enhance the delivery of
this (and other) chemotherapeutic agents (ClinicalTrials.
govNCT02372409). Another glioma clinical trial is investigating
etoposide in combination with sodium thiosulfate in order to
determine if the addition of sodium thiosulfate can protect against
thrombocytopenia (low blood platelet count) noted post etoposide
administration (ClinicalTrials.gov-NCT00075387) [49].
A personalized medicine approach to chemotherapy for brain tumors
can potentially enhance the efficacy of many treatments and minimize
unnecessary exposure to toxic agents that will not benefit the patient. A
critical caveat for the use of topoisomerase II inhibitors (such as etoposide)
relates to delivery effectiveness. Novel delivery techniques may allow
therapeutic intratumoral concentrations of topoisomerase II inhibitors to
be reached andminimize the systemic toxicity commonly associated with
these agents that so far has limited their effectiveness. Our data presented
here suggest that JAG-6A (a significantly smaller molecular weight
compound than etoposide) potently inhibits topoisomerase II and
remains effective independent of oxygenation in both 2D and 3Dmodels.
Together, these data warrant further investigation of JAG-6A for the
treatment of high-grade gliomas.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tranon.2019.07.007.
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